New: our quarterly report on the S&P 500, read from 500 companies’ own filings and calls. Read the Q3 2026 report

AbbVie Inc.

ABBV

Healthcare Drug Manufacturers General

AbbVie Inc.’s revenue for fiscal 2025 (year ended December 2025) was $61.2 billion, up 8.57% from fiscal 2024.

Revenue
+10.3%
EPS
+2,270.0%
Free cash flow
+9.97%
Total debt
+17.7%

Quarter to September 2026, against a year earlier

288.93 5.42 +1.91%
Market cap
$501.2B
P/E
48.8×
Fwd P/E FY26e
37.6×
Dividend yield
2.44%
F-score
8/9
ROIC
20.2%
Net debt / EBITDA
2.6×
Payout ratio
1.2×

Latest quarter Q3 FY2026 · quarter to September 2026

Revenue growth has held between 10% and 13% for four quarters.

Q3 FY2026 and the seven quarters before it
Quarter Revenue, $m Growth, % Op. margin, % EPS, $
Q3 FY26 17,404 10.3 36.0 2.37
Q2 FY26 16,990 10.2 37.9 2.03
Q1 FY26 15,002 12.4 26.6 0.39
Q4 FY25 16,618 10.0 27.3 1.02
Q3 FY25 15,776 9.1 12.1 0.10
Q2 FY25 15,423 6.6 31.7 0.52
Q1 FY25 13,343 8.4 28.0 0.72
Q4 FY24 15,102 5.6 (9.9) (0.02)

Against the consensus: revenue in line ($17.4B v $17.4B); adjusted EPS beat by $0.08 ($3.82 v $3.74).

Growth is on the same quarter a year earlier, and EPS is diluted. Negative figures in brackets.

Outlook

Q4 FY2026 revenue: $18.4 billion

Company guidance, Q3 2026 earnings call.

Reports Feb 3, 2027 · Q4 FY26 · consensus EPS $3.89

All quarters →

Capital & Financial Ratios $m

Size
Market Cap 501,190
Revenue ttm 66,014
Net income ttm 10,348
Free cash flow ttm 18,872
Net debt Q 70,129
Valuation
P/E 48.8 (above 35: high)
Forward P/E FY26e 37.6 (above 35: high)
Price / sales 7.6
Forward P/S FY26e Powerpack
Price / FCF 26.6
Price / book n/m
Financial health
Current ratio Q 0.9 (below 1: weak)
Debt / equity Q n/m
Interest coverage Q 9.0
Growth
Revenue growth FY26e +10.9% (at or above 10%: strong)
EPS growth FY26e +40.1% (at or above 15%: strong)
EPS growth FY27e +16.1% (at or above 15%: strong)
EPS growth, 5 yrs e +21.8% (at or above 15%: strong)
Insiders
Net sold 12m 31
Sells 12m 5
Buys 12m 0
Owned by insiders 0.0%

Green and red mark values outside typical ranges; (Q) is the latest quarter; e marks analysts’ estimates, FY26e the fiscal year ending in 2026; n/m is not meaningful, as a P/E on a loss. How we judge →

Compound annual growth

10y 5y 3y
Sales 10.34% 5.95% 1.75%
Cash Flow 9.71% 1.59% (8.62%)
Earnings (2.04%) (1.94%) (29.17%)
Book Value 0.00% 0.00% 0.00%

Valuation

The price implies free cash flow after share-based pay growing 11.8% a year for ten years. It grew 11.3% a year over the last ten.

Implied
11.8%
10 years, reported
11.3%
Open the model
P/E against its own 10 years 75.08%
10-year low 10-year high
P/S against its own 10 years 99.16%
10-year low 10-year high
EV/Sales against its own 10 years 99.16%
10-year low 10-year high
EV/FCF against its own 10 years 99.16%
10-year low 10-year high

Dividends raised every year since 2018

Yield
2.44%
Annual rate
6.92
Payout ratio
119.1%
Growth, 2018–26
+8.55%/yr
  1. 3.59 ’18
  2. 4.28 ’19 +19
  3. 4.72 ’20 +10
  4. 5.20 ’21 +10
  5. 5.64 ’22 +8
  6. 5.92 ’23 +5
  7. 6.20 ’24 +5
  8. 6.56 ’25 +6
  9. 6.92 ’26 +5
paid change on the year, % Powerpack

Analysts’ price targets Wall Street, collected weekly

Analyst price targets

Analysts’ consensus Wall Street average, updated each weekday

1.6
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to December

Ten-year view Analyst estimates Powerpack
Group Line 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 TTM Sep ’26 Trend 10 yrs 2026e 2027e 2028e Next 3/yr
Income, $m
Income, $m Revenue 25,638 28,216 32,753 33,266 45,804 56,197 58,054 54,318 56,334 61,160 66,014 +10.1% 67,798 73,945 79,776 +9.3%
Gross margin, % 77.25 75.04 76.44 77.64 66.41 68.96 70.00 62.42 69.99 70.24 73.72 (7.0) pt
EBT 7,884 7,727 5,197 8,426 3,398 12,989 13,477 6,250 3,716 6,597 12,814 (2.0%)
EBT margin, % 30.75 27.39 15.87 25.33 7.42 23.11 23.21 11.51 6.60 10.79 19.41 (20.0) pt
Net income 5,953 5,309 5,687 7,882 4,622 11,549 11,845 4,873 4,286 4,233 10,348 (3.7%)
Per share, $
Per share, $ Revenue 15.81 17.68 21.25 22.46 27.48 31.75 32.78 30.72 31.85 34.57 37.32 +9.1%
Earnings 3.63 3.30 3.66 5.28 2.72 6.45 6.63 2.72 2.39 2.36 5.81 (4.7%)
Cash flow 4.34 6.24 8.71 9.00 10.55 12.87 14.08 12.92 10.63 10.76 11.36 +10.6%
Capex (0.30) (0.33) (0.41) (0.37) (0.48) (0.44) (0.39) (0.44) (0.55) (0.69) (0.69) +9.8%
Free cash flow 4.05 5.91 8.30 8.62 10.07 12.42 13.69 12.48 10.08 10.07 10.67 +10.7%
Book value 2.86 3.19 (5.48) (5.52) 7.86 8.72 9.76 5.88 1.90 (1.82) (2.57) n/m
Shares, m 1,622 1,596 1,541 1,481 1,667 1,770 1,771 1,768 1,769 1,769 1,769 +1.0%
Valuation, ×
Valuation, × P/E 17.19 29.91 25.75 16.77 37.47 20.99 24.57 58.54 74.04 96.82 48.80 40.2
P/S 3.95 5.57 4.34 3.94 3.90 4.26 4.95 5.20 5.58 6.61 7.60 4.8
P/B 21.84 30.81 0.00 0.00 13.64 15.53 16.64 27.18 93.45 0.00 0.00 21.9
EV/Sales 5.13 6.54 5.32 4.75 5.59 5.45 5.88 6.06 6.67 7.63 8.66 5.9
EV/FCF 20.06 19.58 13.63 12.37 15.26 13.94 14.09 14.92 21.08 26.18 30.29 17.1
Cash, $m
Cash, $m Operating cash flow 7,041 9,960 13,427 13,324 17,588 22,777 24,943 22,839 18,806 19,030 20,089 +11.7%
Capex (479) (529) (638) (552) (798) (787) (695) (777) (974) (1,214) (1,217) +10.9%
Free cash flow 6,562 9,431 12,789 12,772 16,790 21,990 24,248 22,062 17,832 17,816 18,872 +11.7%
Balance, $m
Balance, $m Working capital 6,406 4,582 (294) 33,934 (4,488) (7,266) (1,075) (4,839) (13,167) (14,227) (5,622) n/m
Net debt 30,419 27,579 32,249 26,804 77,577 66,854 54,042 46,569 61,589 62,239 70,129 +8.3%
Shareholders’ equity 4,636 5,097 (8,446) (8,172) 13,097 15,436 17,287 10,397 3,364 (3,228) (4,538) n/m
Returns, %
Returns, % ROA 9.99 7.76 8.74 10.62 3.85 7.77 8.26 3.52 3.14 3.11 7.32 (6.9) pt
ROIC 16.65 18.26 16.76 43.55 7.83 13.61 15.87 14.00 8.79 15.97 20.23 (0.7) pt
ROE 138.75 109.09 (339.62) (94.86) 187.45 80.90 72.01 34.82 61.59 6,155.88 (288.69) +6,017.1 pt
People
People Employees 30,000 29,000 30,000 30,000 47,000 50,000 50,000 50,000 55,000 57,000 — +7.4%
Revenue/emp, $m 0.85 0.97 1.09 1.11 0.97 1.12 1.16 1.09 1.02 1.07 — +2.6%
Negative figures in brackets.
estimates

All 10 years →

Fiscal years to Dec 2025 · latest quarter Sep 2026 · fundamentals updated Nov 18, 2026

Business profile

Updated

AbbVie is a research-based biopharmaceutical company that develops, manufactures and sells medicines and therapies around the world. It was founded in 2012, is headquartered in North Chicago and is led by Chief Executive Officer Robert A. Michael. Its business operates as a single global segment.

Its medicines span immunology, neuroscience, oncology and eye care. Immunology treatments include Skyrizi, Rinvoq and Humira, which are used for autoimmune and inflammatory conditions. Skyrizi is an injected biologic, while Rinvoq is an oral medicine. The approved uses and available products vary by market.

Where the money comes from and where it goes Fiscal 2025

Fiscal 2025: revenue by products and services, and margins
Skyrizi 17,562 28.71%
Rinvoq 8,304 13.58%
Humira 4,540 7.42%
Botox Therapeutic 3,769 6.16%
Vraylar 3,621 5.92%
Imbruvica 2,869 4.69%
Venclexta 2,792 4.57%
All other 2,627 4.30%
Botox Cosmetic 2,602 4.25%
Other, not broken out 1,545 2.53%
Mavyret 1,317 2.15%
Ubrelvy 1,271 2.08%
Other Aesthetics 1,265 2.07%
Qulipta 1,036 1.69%
Other Eye Care 1,009 1.65%
Juvederm Collection 993 1.62%
Linzess 907 1.48%
Elahere 690 1.13%
Ozurdex 493 0.81%
Vyalev 482 0.79%
Lumigan/Ganfort 410 0.67%
Duodopa 381 0.62%
Epkinly 271 0.44%
Other Neuroscience 207 0.34%
Alphagan/Combigan 197 0.32%
Gross margin 70.24%
Operating margin 24.65%
Pre-tax margin 10.79%

Revenue by segment since 2011

AbbVie Inc. vs peers in Drug Manufacturers General (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
LLY Eli Lilly and Company $1.27T 43.9× 42.2× FY26e +38.61% (above 0%: growing) +16.26% (above 0%: growing) +21.80% (above 0%: growing) 83.88% 36.52% Compare
JNJ Johnson & Johnson $650.7B 40.5× 41.8× FY26e +5.86% (above 0%: growing) −95.75% (below 0%: shrinking) −21.44% (below 0%: shrinking) 68.12% 1.72% Compare
ABBV AbbVie Inc. $501.2B 48.8× 37.6× FY26e +10.32% (above 0%: growing) +2,270.00% (above 0%: growing) +9.97% (above 0%: growing) 75.38% 36.01%
MRK Merck & Co., Inc. $328.6B 137× 105× FY26e +4.68% (above 0%: growing) −12.07% (below 0%: shrinking) −19.27% (below 0%: shrinking) 72.95% 31.90% Compare
NVS Novartis AG $277.7B 28.8× 24.0× FY26e +4.67% (above 0%: growing) −68.81% (below 0%: shrinking) −17.81% (below 0%: shrinking) 75.99% 12.26% Compare
AZN AstraZeneca PLC $272.1B 24.6× 24.2× FY26e +6.70% (above 0%: growing) +23.46% (above 0%: growing) +1.99% (above 0%: growing) 81.82% 27.07% Compare
AMGN Amgen Inc. $237.4B 25.2× 24.0× FY26e +8.45% (above 0%: growing) +19.39% (above 0%: growing) −13.98% (below 0%: shrinking) 73.10% 35.79% Compare
GILD Gilead Sciences, Inc. $207.8B — (loss-making) — (loss-making) +6.83% (above 0%: growing) −20.16% (below 0%: shrinking) +21.13% (above 0%: growing) 81.07% 41.71% Compare
PFE Pfizer Inc. $158.2B 38.8× 18.7× FY26e −0.43% (below 0%: shrinking) −9.68% (below 0%: shrinking) +20.02% (above 0%: growing) 75.71% 22.14% Compare
Median of peers $274.9B 38.8× 24.2× +6.28% −10.87% −5.99% 75.85% 29.49%

All 21 Drug Manufacturers General stocks →

From the latest earnings call

Updated

  • CEO Rob Michael said AbbVie received U.S. approval for a Skyrizi dosing option in Crohn’s disease and is testing combinations with other mechanisms.
  • Chief Commercial Officer Jeff Stewart said Juvemo’s initial demand exceeded expectations, although patients were using enrollment and medical exception processes while access was unavailable.

Analyst rating changes each firm’s latest, last six months

Firm Date Action Rating Target Change
Barclays Nov 20, 2026 Target raised — 325.00 → 335.00 +3.08%
Morgan Stanley Oct 19, 2026 Target raised — 310.00 —
HSBC Oct 6, 2026 Target raised Buy 300.00 → 315.00 +5.00%

Largest institutional holders 13F, quarter to Jun 30, 2026

Held by institutions 75.36%
Held by the ten largest 38.95%
Holder Shares Stake Change
Vanguard 182.90m 10.35% −386.32k
BlackRock 149.49m 8.46% −1.21m
State Street 82.60m 4.67% +1.38m
Capital Group 65.57m 3.71% +3.41m
JPMorgan Chase 47.86m 2.71% −8.88m
Geode Capital Management 47.00m 2.66% +260.85k
Morgan Stanley 38.90m 2.20% +884.23k
UBS 27.11m 1.53% −1.10m
Norges Bank 25.55m 1.45% +25.55m
Bank of America 21.24m 1.20% −2.70m
13F filings for the quarter to 30 June 2026: long positions in US-listed shares reported by managers with $100m or more, ~45 days after the quarter.

AbbVie Inc. (ABBV) Latest News

What happened

  1. Deal AbbVie agreed to pay DISCO Pharmaceuticals $40 million upfront and up to $2.5 billion in milestones, plus tiered royalties, for a solid-tumor therapeutics collaboration.
  2. Results AbbVie reported third-quarter revenue of about $17.4 billion, raised its 2026 outlook to about $67.8 billion and increased its dividend.
  3. Product AbbVie reported Phase 3 TEMPLE results showing QULIPTA was more effective and better tolerated than topiramate for migraine prevention.
  4. Deal AbbVie agreed to license Nxera Pharma’s oral EP4 agonist for inflammatory bowel disease in a deal worth up to $1.37 billion.
13 more headlines
All ABBV news, as stories →

ABBV metrics, ten years each

stockrow.com/ABBV · Data as of Nov 18, 2026 · For information only; not investment advice. · © 2026 stockrow.com